Synthesis and preclinical evaluation of the CRTH2 antagonist [C]MK-7246 as a novel PET tracer and potential surrogate marker for pancreatic beta-cell mass.

Initial preclinical in vitro and in vivo evaluations of [C]MK-7246 show binding and biodistribution properties suitable for PET imaging of CRTH2. Further studies are warranted to assess its potential in β-cell mass imaging and CRTH2 drug development.